BioMerieux
Last update: 10 days ago
Pharmaceuticals
France
Its 50 main executivesIts 4 subsidiaries
Recent executive movements at Institut Merieux
Philippe Archinard who is Chairman of the Board and Chief Executive Officer, Transgene, will be promoted to Chief Operating Officer, Technological Innovation and Scientific Partnerships on Jan. 1, 2021 (news posted on September 17 2020).
Philippe Sans who is Chief Executive Officer, Merieux NutriSciences, will be promoted to Chief Operating Officer, Strategy and Planning on Oct. 1, 2020 (news posted on September 17 2020).
Create an alert
to follow the executive moves at BioMerieux.
BioMerieux is one of the...
Most searched biographies at BioMerieux
- Alexandre Merieux, Chief Executive Officer and Chairman of the Boa...
- Agnes Lemarchand, Independent Director
- Jean-Luc Belingard, Director
Click on an executive to view his biography >
Latest M&A news in Pharmaceuticals.
Tilray and Aphria have announced they will merge (posted on Dec 17, 2020).
AstraZeneca has announced the acquisition of Alexion Pharmaceuticals (posted on Dec 14, 2020).
Bristol-Myers Squibb has acquired MyoKardia (posted on Nov 18, 2020).
Other contacts in the Pharmaceuticals industry
Latest news about BioMerieux
News | Page 38 | bioMérieux Corporate Website
Press Contacts | bioMérieux Corporate Website
BioMerieux on Wikipedia, Google News & Yahoo Finance
BioMerieux on LinkedIn, Twitter & YouTube
BioMerieux has 4 subsidiaries including Astute Medical, BioMerieux Americas and BioMerieux Germany. BioMerieux has 2,034 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Roche (Switzerland). BioMerieux is owned by Institut Merieux.
Contact by email its executives including Alexandre Merieux 
